Long‐Term Health Outcomes of Individuals With Pseudodeficiency Alleles in IDUA May Inform Newborn Screening Practices for Mucopolysaccharidosis Type I
American Journal of Medical Genetics Part A · 2025-04 · 197 (4)
DOI: 10.1002/ajmg.a.63940 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Medical Genetics Part A, online erschienen am 19.11.2024. Verfasst von Lauren O Grady und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Genetics and Metabolism, Massachusetts General Hospital for Children, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Mucopolysaccharidosis I, Neonatal Screening, Iduronidase. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institutes of Health (NIH), NINDS NIH HHS, NICHD NIH HHS.
Abstract (Originalsprache)
Mucopolysaccharidosis type I (MPS I), a lysosomal disorder caused by variants in IDUA , was added to the Recommended Uniform Screening Panel for newborn screening in 2016. Positive screening results for MPS I are commonly due to variants known as “pseudodeficiency alleles,” which decrease in vitro alpha‐L‐iduronidase enzyme activity but are thought to provide sufficient in vivo activity. Despite the historic assumption that these variants are biologically benign, the possibility that they could give rise to complex, multigenic, or attenuated phenotypes has not been systemically evaluated in adults. We completed a retrospective matched cohort study using a hospital‐based biorepository with data from 65,309 participants, we identified 1803 individuals harboring homozygous IDUA pseudodeficiency alleles. Using electronic medical records (EMR), we compared the prevalence of features of MPS I in participants with homozygous pseudodeficiency alleles to a cohort of matched control participants. We found no clinically relevant significant differences between cases and controls nor genotype–phenotype associations across four alleles. These findings provide empiric support that adults with homozygous IDUA pseudodeficiency alleles are unlikely to develop mild symptoms of disease compared with controls. This study provides a proof‐of‐concept model for other nonclassical disease variants related to other inherited metabolic disorders, which is necessary as newborn screening expands.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Genetics and Metabolism, Massachusetts General Hospital for Children, Boston, Massachusetts, USA.
- Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
- Department of Pathology, Laboratory for Molecular Medicine at Mass General Brigham Personalized Medicine, Mass General Hospital, Boston, Massachusetts, USA.
- Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Brigham and Women's Hospital, Mass General Brigham Personalized Medicine, Boston, Massachusetts, USA.
- Department of Medical Genetics and the BC Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.
ORCID-Profile: Lauren O Grady, Lorne Clarke, Amel Karaa
Förderung
- National Institutes of Health (NIH)
- NINDS NIH HHS
- NICHD NIH HHS
- NCATS NIH HHS
- NHGRI NIH HHS
- Sanofi Lysosomal Storage Disease fellowship
- National Human Genome Research Institute
Zitieren
APA
Grady, L. O., Zoltick, E. S., Zouk, H., He, W., Perez, E., Clarke, L., Gold, J., Strong, A., Sahai, I., Yeo, J., Green, R. C., Karaa, A., & Gold, N. B. (2025). Long‐Term Health Outcomes of Individuals With Pseudodeficiency Alleles in IDUA May Inform Newborn Screening Practices for Mucopolysaccharidosis Type I. American Journal of Medical Genetics Part A, 197(4). https://doi.org/10.1002/ajmg.a.63940
Vancouver
Grady LO, Zoltick ES, Zouk H, He W, Perez E, Clarke L, et al. Long‐Term Health Outcomes of Individuals With Pseudodeficiency Alleles in IDUA May Inform Newborn Screening Practices for Mucopolysaccharidosis Type I. American Journal of Medical Genetics Part A. 2025;197(4). doi:10.1002/ajmg.a.63940
BibTeX
@article{Grady2025,
author = {Grady, Lauren O and Zoltick, Emilie S and Zouk, Hana and He, Wei and Perez, Emma and Clarke, Lorne and Gold, Jessica and Strong, Alanna and Sahai, Inderneel and Yeo, Julie and Green, Robert C and Karaa, Amel and Gold, Nina B},
title = {Long‐Term Health Outcomes of Individuals With Pseudodeficiency Alleles in IDUA May Inform Newborn Screening Practices for Mucopolysaccharidosis Type I},
journal = {American Journal of Medical Genetics Part A},
year = {2025},
volume = {197},
number = {4},
doi = {10.1002/ajmg.a.63940}
}
EUVIMED